Digital RESI June Investor Panel

Tuesday, June 8
10:00 – 11:00 AM EST

CORPORATE VENTURE CAPITAL

The Corporate Landscape Morphed & New Opportunities Abound

This panel discusses what strategies are employed by corporate venture capital firms for investments and partnerships with early-stage companies. Potential topics for the panel include:

  • What corporate VCs look for in companies
  • What working with a corporate VC entails
  • What companies should do to be relevant to the corporate VC

Panelists could also discuss the relationship between the corporate venture capital firm and the parent company and how it affects investment criteria.

Tuesday, June 8
2:00 – 3:00 PM EST

IMPACT INVESTORS

Life Science Investors Looking for More Than Financial Returns

This panel features four speakers and a moderator from firms that make equity investments into early-stage companies and organizations with the intent to generate a positive social or environmental impact alongside a financial return. Some of these firms focus on impacting a specific patient population, whereas others have broader goals in creating an impact for their local region, or the world. Topics may include:

  • What is impact investing?
  • How is the investment mandate affected by the impact goal? • How do investors measure and increase the impact of their capital?
  • How should startups approach impact investors for fundraising, and what criteria do they use to evaluate opportunities?
  • What separates an impact investor from a traditional VC?

Panelists will discuss how impact investors provide capital to address challenges in life sciences and healthcare sectors worldwide. While impact investing market is a relatively new trend, panelists will also discuss how companies can successfully fundraise from impact investors and the best way to develop a relationship with relevant investors.

Wednesday, June 9
10:00 – 11:00 AM EST

ANGEL INVESTORS

Explaining the Process of Engagement

This panel focuses on angels in Biotech investment and how angels assess current biotech investment trends and criteria. Topics may include:

  • Types of deals Biotech angels like to do
  • What it’s like to work with an angel investor
  • How biotech and investment landscapes evolving

Angel investors have been one of the first go-to investors as an incredibly important source of capital for fundraising entrepreneurs. Panelists will highlight the perspective of an angel when approaching a deal in the space. Angels will explain their investment preferences and their evaluation criteria, and provide overall advice in how to approach and build relationships with them. The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the trends in angel investment in the bio-pharmaceutical field.

Wednesday, June 9
2:00 – 3:00 PM EST

FAMILY OFFICES

How Do Family Offices View Seed & Series A Rounds?

This panel focusing on understanding how family offices view direct investments in early-stage healthcare opportunities (seed – series A) and how the differ/compare to VCs. Topics may include:

  • Primary differences between institutional VCs and family office investors
  • How family offices source investments / how to get on their radar
  • Trends in the early-stage healthcare investment space

The primary goal of this panel is to help entrepreneurs understand how family offices view early-stage investments in the healthcare space and best practices for approaching, pitching and working with these groups as well as debunking some common misconceptions about family offices.

Thursday, June 10
10:00 – 11:00 AM EST

MEDTECH STRATEGICS

Large Medical Device Firms Seeking External Innovation

In the medical technology sector, major corporations are increasingly looking to external startups and inventors for innovative new technologies. In addition to traditional M&A, these major strategic players in the medtech world are exploring innovative strategies to partner with early stage startups, and our speakers will explore topics such as:

  • How do major corporations find new device technologies that are a fit for their pipelines?
  • What can an early stage startup do to find the right partner?
  • How do partnerships work, and what conditions might a major partner have?
  • What kind of technical and commercial validation will be required to secure a partnership?

The panelists will explore these topics with reference to the technology areas that they are looking at for their future pipelines.

Thursday, June 10
2:00 – 3:00 PM EST

BIG PHARMA

Pipeline Strategy for Preclinical and Early Clinical Assets

In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines. This panel brings together speakers from various big pharma companies discussing topics such as:

  • How big pharma sources assets
  • The evaluation and investment process
  • Key factors of interest
  • How early-stage big pharma is willing to look

These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.